Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer

NCT00304460 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

138

Enrollment

NIH

Sponsor class

Conditions

Metastatic Melanoma
Renal Cell Cancer

Interventions

BIOLOGICAL: aldesleukin

Sponsor

National Cancer Institute (NCI)